INVA · NASDAQ
Innoviva (INVA) Stock Price & Fundamentals
Innoviva (INVA) closed at $623.32 on Oct 9, 2026, up 1.05% from the previous close of $616.85.
Share price, past year
1Y +6.01%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $623.32 |
| Sep 30, 2026 | $605.82 |
| Aug 31, 2026 | $624.03 |
| Jul 31, 2026 | $619.33 |
| Jun 30, 2026 | $611.34 |
| May 29, 2026 | $575.20 |
| Apr 30, 2026 | $569.42 |
| Mar 31, 2026 | $539.27 |
| Feb 27, 2026 | $557.38 |
| Jan 30, 2026 | $566.67 |
| Dec 31, 2025 | $560.93 |
| Nov 28, 2025 | $575.17 |
| Oct 31, 2025 | $554.71 |
Key statistics
- Market cap
- $45.28B
- P/E (TTM)
- 143.3
- EPS (TTM)
- $4.35
- Revenue (TTM)
- $440.00M
- Net income (TTM)
- —
- Shares outstanding
- 72.6M
- Dividend yield
- —
- 52-week range
- $533.69 – $640.79
Innoviva's market cap is $45.28B, based on a share price of $623.32 and 72.6M shares outstanding as of Jun 30, 2026.
Financials
Innoviva reported revenue of $411.33M for fiscal 2025, up 14.67% from fiscal 2024.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $411.33M | +14.7% | — | — | $3.30 | $195.80M |
| FY2024ended Dec 31, 2024 | $358.71M | +15.5% | — | — | $0.36 | $188.42M |
| FY2023ended Dec 31, 2023 | $310.46M | −6.3% | — | — | $2.20 | $140.65M |
| FY2022ended Dec 31, 2022 | $331.34M | −15.5% | — | — | $2.37 | $201.66M |
| FY2021ended Dec 31, 2021 | $391.87M | +16.4% | — | — | $2.87 | $363.81M |
| FY2020ended Dec 31, 2020 | $336.79M | +29.0% | — | — | $2.02 | $313.10M |
| FY2019ended Dec 31, 2019 | $261.02M | 0.0% | — | — | $1.43 | $257.45M |
| FY2018ended Dec 31, 2018 | $261.00M | +20.2% | — | — | $3.53 | $223.53M |
| FY2017ended Dec 31, 2017 | $217.22M | +62.6% | — | — | $1.17 | $141.75M |
| FY2016ended Dec 31, 2016 | $133.57M | — | — | — | $0.53 | $60.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $119.59M | — | −$1.14 |
| Q1 FY2026ended Mar 31, 2026 | $97.99M | — | $2.22 |
| Q4 FY2025ended Dec 31, 2025 | $114.61M | — | $2.19 |
| Q3 FY2025ended Sep 30, 2025 | $107.80M | — | $1.08 |
| Q2 FY2025ended Jun 30, 2025 | $100.28M | — | $0.77 |
| Q1 FY2025ended Mar 31, 2025 | $88.63M | — | −$0.74 |
| Q4 FY2024ended Dec 31, 2024 | $91.81M | — | $0.43 |
| Q3 FY2024ended Sep 30, 2024 | $89.51M | — | $0.02 |
Company profile
- Name
- Innoviva, Inc.
- Ticker
- INVA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001080014
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- May 18, 2026
- May 6, 2026
- May 6, 2026
- May 4, 2026
- Mar 27, 2026
- Feb 25, 2026
Frequently asked questions
What is Innoviva's stock price?
Innoviva (INVA) closed at $623.32 on Oct 9, 2026, up 1.05% from the previous close of $616.85.
What is Innoviva's market cap?
Innoviva's market cap is $45.28B, based on a share price of $623.32 and 72.6M shares outstanding as of Jun 30, 2026.
How much revenue does Innoviva make?
Innoviva reported revenue of $411.33M for fiscal 2025, up 14.67% from fiscal 2024.
What is INVA's P/E ratio?
Innoviva's price-to-earnings ratio is 143.3, based on trailing twelve-month diluted EPS of $4.35.
Does Innoviva pay a dividend?
Innoviva's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Innoviva, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures